Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 30 2022 - 4:43PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced it granted inducement awards
on December 30, 2022.
Two individuals hired by Adicet in December 2022 received, in
the aggregate, non-qualified stock options to purchase 47,200
shares of Adicet’s common stock with an exercise price of $8.94 per
share, the closing price of Adicet’s common stock as reported by
Nasdaq on December 30, 2022. One-fourth of the shares underlying
each employee’s option will vest on the one-year anniversary of
each recipient’s start date and thereafter the remaining
three-fourths of the shares underlying each employee’s option will
vest in thirty-six substantially equal monthly installments, such
that the shares underlying the option granted to each employee will
be fully vested on the fourth anniversary of the recipient’s start
date, in each case, subject to each such employee’s continued
employment with Adicet on such vesting dates.
All of the above-described awards were granted outside of
Adicet’s stockholder-approved equity incentive plans pursuant to
Adicet’s 2022 Inducement Plan (the Inducement Plan), which was
adopted by the board of directors in January 2022. The awards were
authorized by the compensation committee of the board of directors,
which is comprised solely of independent directors, as a material
inducement to the employees entering into employment with Adicet in
accordance with Nasdaq Listing Rule 5635(c)(4).
About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical
stage biotechnology company discovering and developing allogeneic
gamma delta T cell therapies for cancer. Adicet is advancing a
pipeline of “off-the-shelf” gamma delta T cells, engineered with
chimeric antigen receptors (CARs) and adaptors (CAds), to enhance
selective tumor targeting and facilitate innate and adaptive
anti-tumor immune response for durable activity in patients. For
more information, please visit our website at
https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221230005221/en/
Adicet Bio., Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com Janhavi Mohite Stern Investor
Relations, Inc. 212-362-1200 janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Sep 2023 to Sep 2024